Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Genetics may influence risk for breast cancer after chest radiotherapy to treat...

Dr Lindsay Morton - National Cancer Institute, Bethesda, USA

Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer ( Dr Lindsay Morton - National Cancer Institute, Bethesda, USA )

A presurgery combination therapy may improve outcomes for women with Her2...

Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania...

A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )

5 year survival rates for nivolumab-treated metastatic melanoma patients much...

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical...

Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA

CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )

New investigational targeted therapeutic, entrectinib, shows early promise

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA

New investigational targeted therapeutic, entrectinib, shows early promise ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )

Galectins in tumour immunity

Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos...

Galectins in tumour immunity ( Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina )

Treatment of relapsed myeloma with novel targeted and immune therapies

Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA

Treatment of relapsed myeloma with novel targeted and immune therapies ( Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA )

Targeting T regs in tumours

Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA

Targeting T regs in tumours ( Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA )

Multiplex IHC as biomarkers for cancer immunotherapy

Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA

Multiplex IHC as biomarkers for cancer immunotherapy ( Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA )

Direct activation of STING in the tumour microenvironment leads to potent and...

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )

Successes and challenges in designing combination immunotherapy clinical trials...

Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA

Successes and challenges in designing combination immunotherapy clinical trials for breast cancer ( Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA )

Breast cancer risk prediction models improved by adding multiple biological...

Dr Xuehong Zhang - Dana-Farber Cancer Institute, Boston, USA

Breast cancer risk prediction models improved by adding multiple biological markers of risk ( Dr Xuehong Zhang - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer